Is GRAIL Inc. (GRAL) a Buy, Sell, or Hold?
GRAIL Inc.
NASDAQ:GRAL
$73.12 USD
$1.32 (1.84%)
- Volume
- 386.13K
- Average Volume
- 687.16K
- Market Capitalization
- $3.14B
- P/E Ratio
- -7.05
- Dividend Yield
- 0.00%
- Price Target
- $60.00
- Year High
- $118.84
- Year Low
- $29.95
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $11.74
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Robert Ragusa |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | GRAL |
| CUSIP | 384747101 |
| CIK | 0001699031 |
| Web | http://www.grail.com |
| Phone | 833-694-2553 |
| Currency | USD |
| Employees | 910 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.02 |
| Payout Ratio | 0.00 |
| Current Ratio | 11.74 |
| Quick Ratio | 11.51 |
| Cash Ratio | 0.93 |
Sales & Book Value
| Annual Sales | $147.17M |
| Price / Sales | 20.10 |
| Cash Flow | -7.17 |
| Price / Cash Flow | -10.77 |
| Price / Book | 1.19 |
Price Target and Rating
| Average Stock Price Forecast | $60.00 |
| High Stock Price Forecast | $130.00 |
| Low Stock Price Forecast | $56.00 |
| Forecast Upside/Downside | 21.87% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 6 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-11.11 |
| Trailing P/E Ratio | -7.05 |
| PEG Ratio | -0.06 |
| P/E Growth | -0.06 |
| Net Income | $-408.35M |
| Net Margin | -253.22% |
| Pretax Margin | -330.27% |
| Return on Equity | -16.42% |
| Return on Assets | -14.10% |
Financials Score
| AltmanZ Score | 0.78 |
| Piotroski Score | 4.00 |
| Working Capital | 802.64M |
| Total Assets | 2.8B |
| Ebit | -493.61M |
| Market Cap | 3.08B |
| Total Liabilities | 302.79M |
Poll Results
About GRAIL Inc. (NASDAQ:GRAL) Stock
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 20 ... 15 and is headquartered in Menlo Park, California.
2026-07-14 21:41:00
SAN FRANCISCO, July 14, 2026 /PRNewswire/ -- On February 20, 2026, GRAIL, Inc. (NASDAQ: GRAL) shed over $2.2 billion of market capitalization after surprising investors with its NHS-Galleri Trial readout. The news caused huge investor losses and triggered a securities class action lawsuit seeking to represent investors who purchased or otherwise acquired shares of GRAIL common stock between May 13, 2025 and February 19, 2026.
2026-07-14 17:09:00
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against GRAIL, Inc. (“Grail” or the “Company”) (NASDAQ: GRAL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
2026-07-14 16:39:00
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GRAIL, Inc. (NASDAQ: GRAL) between May 13, 2025 and February 19, 2026, inclusive (the “Class Period”), of the important August 4, 2026 lead plaintiff deadline.
Grail, Inc. (GRAL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
2026-07-14 12:00:00
LOS ANGELES, July 14, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Grail, Inc. ("Grail" or the "Company") (NASDAQ:GRAL). IF YOU SUFFERED A LOSS ON YOUR GRAIL INVESTMENTS, CLICK HERE BEFORE AUGUST 4, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
2026-07-14 12:00:00
New York, New York--(Newsfile Corp. - July 14, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
2026-07-14 10:07:00
NEW YORK, July 14, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GRAIL, Inc. (NASDAQ: GRAL). Shareholders who purchased shares of GRAL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
2026-07-14 09:48:00
Wall Street's Reassessment of Grail: How Analyst Expectations Built on Positive NHS-Galleri Representations Collapsed Alongside GRAL's $51.32 Per-Share Decline Wall Street's Reassessment of Grail: How Analyst Expectations Built on Positive NHS-Galleri Representations Collapsed Alongside GRAL's $51.32 Per-Share Decline
2026-07-14 06:17:00
A securities fraud class action lawsuit has been filed on behalf of GRAIL investors after its stock plummeted 50% because GRAIL allegedly misled investors relating to GRAIL's NHS-Galleri cancer trial, potentially violating federal securities laws. NEW YORK, July 14, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against GRAIL, Inc. (NASDAQ:GRAL) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.
Frequently Asked Questions
-
What is the current GRAIL Inc. (GRAL) stock price?
-
GRAIL Inc.(NASDAQ:GRAL) stock price is $73.12 in the last trading session. During the trading session, GRAL stock reached the peak price of $118.84 while $29.95 was the lowest point it dropped to. The percentage change in GRAL stock occurred in the recent session was 1.84% while the dollar amount for the price change in GRAL stock was $1.32.
-
GRAL's industry and sector of operation?
-
The NASDAQ listed GRAL is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GRAL?
-
Eric T. Fung | Senior Vice President of Clinical Development
Joshua J. Ofman | Chief Executive Officer & Director
Satnam Alag | Chief Technology Officer
Andrew John Partridge | Chief Growth Officer
Paul Ciccolella | Senior Vice President of Global Development & Operations -
How many employees does GRAL have?
-
Number of GRAL employees currently stands at 910. GRAL operates from 1525 O’Brien Drive, Menlo Park, CA 94025, US.
-
Link for GRAL official website?
-
Official Website of GRAL is: http://www.grail.com
-
How do I contact GRAL?
-
GRAL could be contacted at phone #833-694-2553 and can also be accessed through its website. GRAL operates from 1525 O’Brien Drive, Menlo Park, CA 94025, US.
-
How many shares of GRAL are traded daily?
-
The average number of GRAL shares traded daily for last 3 months was 687.16K.
-
What is the market cap of GRAL currently?
-
The market value of GRAL currently stands at $3.14B with its latest stock price at $73.12